SEPNSepterna, Inc.
- Market cap
- $1.89B
- as of 2026-10-23
- Latest close
- $40.41
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Biotechnology
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2024-10-28
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Bhatt ElizabethPresident and COO | Oct 15 | Oct 19 | M | 4,000 | $6.81 | $27,240 | 178,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Oct 15 | Oct 19 | S | 1,094 | $36.87 | Sale −$40,337 | 177,115 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Oct 15 | Oct 19 | S | 2,906 | $37.61 | Sale −$109,307 | 174,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Oct 15 | Oct 19 | M · derivative | 4,000 | $6.81 | $27,240 | 58,230 | Yes | Form 4 |
| Patni RajivChief Medical Officer | Sep 8 | Sep 10 | A · derivative | 275,000 | $37.37 | $10,276,750 | 275,000 | No | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Sep 1 | Sep 3 | M | 3,333 | $2.76 | $9,199 | 99,745 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Sep 1 | Sep 3 | S | 3,333 | $37.83 | Sale −$126,087 | 96,412 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Sep 1 | Sep 3 | M · derivative | 3,333 | $2.76 | $9,199 | 9,085 | Yes | Form 4 |
| Third Rock Ventures GP VI, L.P. | Aug 12 | Aug 14 | S | 147,059 | $50.27 | Sale −$7,392,656 | 6,068,532 | Yes | Form 4 |
| Third Rock Ventures GP VI, L.P. | Aug 12 | Aug 14 | S | 141 | $51.08 | Sale −$7,202 | 6,068,391 | Yes | Form 4 |
| Shah Rajeev M. | Aug 12 | Aug 14 | S | 746,500 | $42.50 | Sale −$31,726,250 | 4,777,415 | No | Form 4 |
| Shah Rajeev M. | Aug 12 | Aug 14 | S | 746,500 | $42.50 | Sale −$31,726,250 | 725,443 | No | Form 4 |
| Bhatt ElizabethPresident and COO | Aug 11 | Aug 13 | M | 18,681 | $6.81 | $127,218 | 192,890 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Aug 11 | Aug 13 | M | 6,319 | $2.76 | $17,440 | 199,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Aug 11 | Aug 13 | S | 25,000 | $44.00 | Sale −$1,100,000 | 174,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Aug 11 | Aug 13 | M · derivative | 18,681 | $6.81 | $127,218 | 62,230 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Aug 11 | Aug 13 | M · derivative | 6,319 | $2.76 | $17,440 | 82,332 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Aug 3 | Aug 5 | M | 1,816 | $2.76 | $5,012 | 98,228 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Aug 3 | Aug 5 | M | 1,518 | $2.76 | $4,190 | 99,746 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Aug 3 | Aug 5 | S | 1,000 | $33.98 | Sale −$33,980 | 98,746 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Aug 3 | Aug 5 | S | 2,334 | $34.68 | Sale −$80,943 | 96,412 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Aug 3 | Aug 5 | M · derivative | 1,816 | $2.76 | $5,012 | 5,227 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Aug 3 | Aug 5 | M · derivative | 1,518 | $2.76 | $4,190 | 12,418 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Jul 15 | Jul 17 | M | 4,000 | $6.81 | $27,240 | 178,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Jul 15 | Jul 17 | S | 4,000 | $33.99 | Sale −$135,960 | 174,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Jul 15 | Jul 17 | M · derivative | 4,000 | $6.81 | $27,240 | 80,911 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jul 1 | Jul 2 | M | 3,333 | $2.76 | $9,199 | 99,745 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jul 1 | Jul 2 | S | 2,100 | $34.10 | Sale −$71,610 | 97,645 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jul 1 | Jul 2 | S | 1,233 | $34.81 | Sale −$42,921 | 96,412 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jul 1 | Jul 2 | M · derivative | 3,333 | $2.76 | $9,199 | 7,043 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 29 | Jun 30 | M | 2,178 | $6.81 | $14,832 | 2,971 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 29 | Jun 30 | S | 2,178 | $35.18 | Sale −$76,622 | 793 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 29 | Jun 30 | M · derivative | 2,178 | $6.81 | $14,832 | 20,865 | Yes | Form 4 |
| Ezekowitz Alan | Jun 26 | Jun 30 | A · derivative | 15,000 | $37.34 | $560,100 | 15,000 | No | Form 4 |
| Simson Jake | Jun 26 | Jun 30 | A · derivative | 15,000 | $37.34 | $560,100 | 15,000 | No | Form 4 |
| Gottesdiener Keith Michael | Jun 26 | Jun 30 | A · derivative | 11,260 | $37.34 | $420,448 | 11,260 | No | Form 4 |
| Tong Jeffrey K | Jun 26 | Jun 30 | A · derivative | 15,000 | $37.34 | $560,100 | 15,000 | No | Form 4 |
| Coulie Bernard | Jun 26 | Jun 30 | A · derivative | 15,000 | $37.34 | $560,100 | 15,000 | No | Form 4 |
| Sharp Shalini | Jun 26 | Jun 30 | A · derivative | 15,000 | $37.34 | $560,100 | 15,000 | No | Form 4 |
| Bassan Abraham | Jun 26 | Jun 30 | A · derivative | 15,000 | $37.34 | $560,100 | 15,000 | No | Form 4 |
| Kolchinsky Peter | Jun 26 | Jun 30 | A · derivative | 15,000 | $37.34 | $560,100 | 15,000 | No | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jun 22 | Jun 24 | M | 10,529 | $2.76 | $29,060 | 106,941 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jun 22 | Jun 24 | M | 4,471 | $11.70 | $52,311 | 111,412 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jun 22 | Jun 24 | S | 8,000 | $35.10 | Sale −$280,800 | 103,412 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jun 22 | Jun 24 | S | 7,000 | $35.97 | Sale −$251,790 | 96,412 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jun 22 | Jun 24 | M · derivative | 10,529 | $2.76 | $29,060 | 10,376 | Yes | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Jun 22 | Jun 24 | M · derivative | 4,471 | $11.70 | $52,311 | 25,529 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 12 | Jun 16 | M | 6,250 | $11.70 | $73,125 | 7,043 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 12 | Jun 16 | S | 6,250 | $35.08 | Sale −$219,250 | 793 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 12 | Jun 16 | M · derivative | 6,250 | $11.70 | $73,125 | 23,750 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | M | 4,355 | $1.55 | $6,750 | 5,148 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | M | 943 | $2.76 | $2,603 | 6,091 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | M | 637 | $2.76 | $1,758 | 6,728 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | S | 1,700 | $27.78 | Sale −$47,226 | 5,028 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | S | 1,346 | $28.79 | Sale −$38,751 | 3,682 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | S | 2,889 | $29.66 | Sale −$85,688 | 793 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | M · derivative | 4,355 | $1.55 | $6,750 | 11,614 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | M · derivative | 943 | $2.76 | $2,603 | 2,517 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Jun 1 | Jun 3 | M · derivative | 637 | $2.76 | $1,758 | 4,464 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | May 26 | May 28 | M | 11,798 | $6.81 | $80,344 | 12,591 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | May 26 | May 28 | S | 11,798 | $30.06 | Sale −$354,648 | 793 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | May 26 | May 28 | M · derivative | 11,798 | $6.81 | $80,344 | 23,043 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Apr 15 | Apr 17 | M | 4,000 | $6.81 | $27,240 | 178,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Apr 15 | Apr 17 | S | 2,573 | $23.76 | Sale −$61,134 | 175,636 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Apr 15 | Apr 17 | S | 1,101 | $25.24 | Sale −$27,789 | 174,535 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Apr 15 | Apr 17 | S | 326 | $25.86 | Sale −$8,430 | 174,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Apr 15 | Apr 17 | M · derivative | 4,000 | $6.81 | $27,240 | 84,911 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | M | 53,714 | $1.55 | $83,257 | 54,507 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | M | 11,638 | $2.76 | $32,121 | 66,145 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | M | 5,101 | $2.76 | $14,079 | 71,246 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | S | 4,090 | $27.51 | Sale −$112,516 | 67,156 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | S | 66,363 | $28.14 | Sale −$1,867,455 | 793 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | M · derivative | 53,714 | $1.55 | $83,257 | 15,969 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | M · derivative | 11,638 | $2.76 | $32,121 | 3,460 | Yes | Form 4 |
| Shaikhly SamiraChief People Officer | Mar 2 | Mar 4 | M · derivative | 5,101 | $2.76 | $14,079 | 5,101 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Feb 18 | Feb 20 | M | 4,000 | $6.81 | $27,240 | 178,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Feb 18 | Feb 20 | S | 2,200 | $28.46 | Sale −$62,612 | 176,009 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Feb 18 | Feb 20 | S | 1,800 | $29.58 | Sale −$53,244 | 174,209 | Yes | Form 4 |
| Bhatt ElizabethPresident and COO | Feb 18 | Feb 20 | M · derivative | 4,000 | $6.81 | $27,240 | 88,911 | Yes | Form 4 |
| Wilson Mark AndrewChief Legal Officer | Feb 6 | Feb 10 | A · derivative | 165,000 | $25.41 | $4,192,650 | 165,000 | No | Form 4 |
| Finer JeffreyChief Executive Officer | Feb 6 | Feb 10 | A · derivative | 400,000 | $25.41 | $10,164,000 | 400,000 | No | Form 4 |
| Bhatt ElizabethPresident and COO | Feb 6 | Feb 10 | A · derivative | 155,000 | $25.41 | $3,938,550 | 155,000 | No | Form 4 |
| Kim Jae B.Chief Medical Officer | Feb 6 | Feb 10 | A · derivative | 125,000 | $25.41 | $3,176,250 | 125,000 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Feb 6 | Feb 10 | A · derivative | 125,000 | $25.41 | $3,176,250 | 125,000 | No | Form 4 |
| Shaikhly SamiraChief People Officer | Feb 6 | Feb 10 | A · derivative | 80,000 | $25.41 | $2,032,800 | 80,000 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Feb 6 | Feb 10 | A · derivative | 80,000 | $25.41 | $2,032,800 | 80,000 | No | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Feb 6 | Feb 10 | A · derivative | 80,000 | $25.41 | $2,032,800 | 80,000 | No | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Nov 10, 2025 | Nov 13, 2025 | S | 3,501 | $18.06 | Sale −$63,228 | 92,911 | No | Form 4 |
| Gottesdiener Keith Michael | Sep 25, 2025 | Sep 29, 2025 | A · derivative | 33,246 | $16.75 | $556,871 | 33,246 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Aug 18, 2025 | Aug 19, 2025 | M | 10,452 | $2.76 | $28,848 | 10,452 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Aug 18, 2025 | Aug 19, 2025 | M | 4,935 | $2.76 | $13,621 | 15,387 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Aug 18, 2025 | Aug 19, 2025 | M | 7,621 | $6.81 | $51,899 | 23,008 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Aug 18, 2025 | Aug 19, 2025 | M · derivative | 10,452 | $2.76 | $28,848 | 10,453 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Aug 18, 2025 | Aug 19, 2025 | M · derivative | 4,935 | $2.76 | $13,621 | 9,001 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Aug 18, 2025 | Aug 19, 2025 | M · derivative | 7,621 | $6.81 | $51,899 | 33,027 | No | Form 4 |
| Klein UweSVP, Biological Sciences | Aug 7, 2025 | Aug 11, 2025 | A · derivative | 30,000 | $11.70 | $351,000 | 30,000 | No | Form 4 |
| Long Daniel D.SVP, Drug Discovery | Aug 7, 2025 | Aug 11, 2025 | A · derivative | 30,000 | $11.70 | $351,000 | 30,000 | No | Form 4 |
| Finer JeffreyChief Executive Officer | Aug 7, 2025 | Aug 11, 2025 | A · derivative | 210,000 | $11.70 | $2,457,000 | 210,000 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Aug 7, 2025 | Aug 11, 2025 | A · derivative | 37,500 | $11.70 | $438,750 | 37,500 | No | Form 4 |
| Kim Jae B.Chief Medical Officer | Aug 7, 2025 | Aug 11, 2025 | A · derivative | 55,000 | $11.70 | $643,500 | 55,000 | No | Form 4 |
| Bhatt ElizabethPresident and COO | Aug 7, 2025 | Aug 11, 2025 | A · derivative | 95,000 | $11.70 | $1,111,500 | 95,000 | No | Form 4 |
| Shaikhly SamiraChief People Officer | Aug 7, 2025 | Aug 11, 2025 | A · derivative | 30,000 | $11.70 | $351,000 | 30,000 | No | Form 4 |
| Ezekowitz Alan | Jun 17, 2025 | Jun 20, 2025 | A · derivative | 16,623 | $10.24 | $170,220 | 16,623 | No | Form 4 |
| Bassan Abraham | Jun 17, 2025 | Jun 20, 2025 | A · derivative | 16,623 | $10.24 | $170,220 | 16,623 | No | Form 4 |
| Simson Jake | Jun 17, 2025 | Jun 20, 2025 | A · derivative | 16,623 | $10.24 | $170,220 | 16,623 | No | Form 4 |
| Coulie Bernard | Jun 17, 2025 | Jun 20, 2025 | A · derivative | 16,623 | $10.24 | $170,220 | 16,623 | No | Form 4 |
| Tong Jeffrey K | Jun 17, 2025 | Jun 20, 2025 | A · derivative | 16,623 | $10.24 | $170,220 | 16,623 | No | Form 4 |
| Sharp Shalini | Jun 17, 2025 | Jun 20, 2025 | A · derivative | 16,623 | $10.24 | $170,220 | 16,623 | No | Form 4 |
| RA Capital Healthcare Fund LP | Jun 17, 2025 | Jun 20, 2025 | A · derivative | 16,623 | $10.24 | $170,220 | 16,623 | No | Form 4 |
| Finer JeffreyCEO and President | Apr 3, 2025 | Apr 4, 2025 | M | 5,000 | $2.76 | $13,800 | 826,907 | No | Form 4 |
| Finer JeffreyCEO and President | Apr 3, 2025 | Apr 4, 2025 | M · derivative | 5,000 | $2.76 | $13,800 | 397,212 | No | Form 4 |
| Finer JeffreyCEO and President | Apr 2, 2025 | Apr 4, 2025 | M | 50,000 | $2.76 | $138,000 | 821,907 | No | Form 4 |
| Finer JeffreyCEO and President | Apr 2, 2025 | Apr 4, 2025 | M · derivative | 50,000 | $2.76 | $138,000 | 402,212 | No | Form 4 |
| Ezekowitz Alan | Mar 7, 2025 | Mar 10, 2025 | P | 13,319 | $6.93 | Purchase +$92,301 | 117,420 | No | Form 4 |
| Ezekowitz Alan | Mar 6, 2025 | Mar 6, 2025 | P | 41,355 | $6.00 | Purchase +$248,130 | 104,101 | No | Form 4 |
| Ezekowitz Alan | Mar 5, 2025 | Mar 6, 2025 | P | 37,835 | $5.82 | Purchase +$220,200 | 62,746 | No | Form 4 |
| Ezekowitz Alan | Mar 4, 2025 | Mar 6, 2025 | P | 7,491 | $6.35 | Purchase +$47,568 | 24,911 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Feb 27, 2025 | Feb 27, 2025 | P | 3,718 | $5.85 | Purchase +$21,750 | 40,000 | No | Form 4 |
| Finer JeffreyCEO and President | Feb 27, 2025 | Feb 27, 2025 | P | 3,000 | $5.80 | Purchase +$17,400 | 771,907 | No | Form 4 |
| Finer JeffreyCEO and President | Feb 26, 2025 | Feb 27, 2025 | P | 4,000 | $5.70 | Purchase +$22,800 | 768,907 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Feb 25, 2025 | Feb 27, 2025 | P | 6,282 | $5.59 | Purchase +$35,116 | 36,282 | No | Form 4 |
| Finer JeffreyCEO and President | Feb 25, 2025 | Feb 27, 2025 | P | 10,000 | $5.68 | Purchase +$56,800 | 764,907 | No | Form 4 |
| Third Rock Ventures GP V, LP | Feb 24, 2025 | Feb 26, 2025 | P | 18,861 | $6.00 | Purchase +$113,166 | 4,211,659 | No | Form 4 |
| Third Rock Ventures GP V, LP | Feb 21, 2025 | Feb 24, 2025 | P | 427,668 | $5.94 | Purchase +$2,540,348 | 4,192,798 | No | Form 4 |
| Third Rock Ventures GP V, LP | Feb 20, 2025 | Feb 24, 2025 | P | 612,674 | $5.92 | Purchase +$3,627,030 | 3,765,130 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Feb 21, 2025 | Feb 21, 2025 | P | 5,000 | $5.85 | Purchase +$29,250 | 30,000 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Feb 20, 2025 | Feb 21, 2025 | P | 14,500 | $5.88 | Purchase +$85,260 | 25,000 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Feb 19, 2025 | Feb 21, 2025 | P | 10,500 | $5.51 | Purchase +$57,855 | 10,500 | No | Form 4 |
| Labrucherie Gil MChief Financial Officer | Feb 7, 2025 | Feb 7, 2025 | A · derivative | 222,000 | $13.09 | $2,905,980 | 222,000 | No | Form 4 |
| Shah Rajeev M. | Oct 28, 2024 | Oct 30, 2024 | C | 1,695,515 | not reported | not reported | 1,695,515 | No | Form 4 |
| Shah Rajeev M. | Oct 28, 2024 | Oct 30, 2024 | C | 1,130,343 | not reported | not reported | 1,130,343 | No | Form 4 |
| Shah Rajeev M. | Oct 28, 2024 | Oct 30, 2024 | P | 3,828,400 | $18.00 | Purchase +$68,911,200 | 5,523,915 | No | Form 4 |
| Shah Rajeev M. | Oct 28, 2024 | Oct 30, 2024 | P | 341,600 | $18.00 | Purchase +$6,148,800 | 1,471,943 | No | Form 4 |
| Shah Rajeev M. | Oct 28, 2024 | Oct 30, 2024 | C · derivative | 14,598,896 | not reported | not reported | not reported | No | Form 4 |
| Shah Rajeev M. | Oct 28, 2024 | Oct 30, 2024 | C · derivative | 9,732,596 | not reported | not reported | not reported | No | Form 4 |
| Trv Gp V, LLC | Oct 28, 2024 | Oct 28, 2024 | C | 4,790,773 | $0.00 | $0 | 5,845,091 | No | Form 4 |
| Trv Gp V, LLC | Oct 28, 2024 | Oct 28, 2024 | C | 2,872,956 | $0.00 | $0 | 2,872,956 | No | Form 4 |
| Trv Gp V, LLC | Oct 28, 2024 | Oct 28, 2024 | P | 370,500 | $18.00 | Purchase +$6,669,000 | 6,215,591 | No | Form 4 |
| Trv Gp V, LLC | Oct 28, 2024 | Oct 28, 2024 | P | 279,500 | $18.00 | Purchase +$5,031,000 | 3,152,456 | No | Form 4 |
| Trv Gp V, LLC | Oct 28, 2024 | Oct 28, 2024 | C · derivative | 41,250,000 | $0.00 | $0 | not reported | No | Form 4 |
| Trv Gp V, LLC | Oct 28, 2024 | Oct 28, 2024 | C · derivative | 24,737,017 | $0.00 | $0 | not reported | No | Form 4 |